BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22358305)

  • 1. Ingenol mebutate: an introduction.
    Fallen RS; Gooderham M
    Skin Therapy Lett; 2012 Feb; 17(2):1-3. PubMed ID: 22358305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
    Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
    Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
    Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
    J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ingenol mebutate (Picato) for actinic keratosis.
    Med Lett Drugs Ther; 2012 Apr; 54(1389):35-6. PubMed ID: 22538622
    [No Abstract]   [Full Text] [Related]  

  • 5. Ingenol mebutate gel for actinic keratosis.
    Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
    N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermoscopic monitoring of efficacy of ingenol mebutate in the treatment of pigmented and non-pigmented basal cell carcinomas.
    Diluvio L; Bavetta M; Di Prete M; Orlandi A; Bianchi L; Campione E
    Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27860083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.
    Berman B
    Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superficial basal cell carcinoma successfully treated with ingenol mebutate gel 0.05%.
    Cantisani C; Paolino G; Cantoresi F; Faina V; Richetta AG; Calvieri S
    Dermatol Ther; 2014; 27(6):352-4. PubMed ID: 25052730
    [No Abstract]   [Full Text] [Related]  

  • 9. Ingenol mebutate: potential for further development of cancer immunotherapy.
    Doan HQ; Gulati N; Levis WR
    J Drugs Dermatol; 2012 Oct; 11(10):1156-7. PubMed ID: 23134979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial.
    Siller G; Rosen R; Freeman M; Welburn P; Katsamas J; Ogbourne SM
    Australas J Dermatol; 2010 May; 51(2):99-105. PubMed ID: 20546215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP).
    Tzogani K; Nagercoil N; Hemmings RJ; Samir B; Gardette J; Demolis P; Salmonson T; Pignatti F
    Eur J Dermatol; 2014; 24(4):457-63. PubMed ID: 25115145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PICATO (ingenol mebutate 0.015% and 0.05% gels): a novel treatment for actinic keratosis.
    Abramovits W; Oquendo M; Vincent KD; Gupta AK
    Skinmed; 2013; 11(2):111-5. PubMed ID: 23745230
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses.
    Lebwohl M; Shumack S; Stein Gold L; Melgaard A; Larsson T; Tyring SK
    JAMA Dermatol; 2013 Jun; 149(6):666-70. PubMed ID: 23553119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ingenol mebutate: a new option for actinic keratosis treatment.
    Gras J
    Drugs Today (Barc); 2013 Jan; 49(1):15-22. PubMed ID: 23362492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice.
    Bettencourt MS
    J Drugs Dermatol; 2014 Mar; 13(3):269-73. PubMed ID: 24595570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.
    Gupta AK; Paquet M
    J Cutan Med Surg; 2013; 17(3):173-9. PubMed ID: 23673300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ingenol mebutate for pigmented superficial basal cell carcinomas: evaluation by confocal microscopy.
    Monfrecola G; Scalvenzi M; Costa C; Cantelli M; Fabbrocini G
    G Ital Dermatol Venereol; 2019 Oct; 154(5):586-588. PubMed ID: 27284778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rapidly growing squamous cell carcinoma after ingenol mebutate treatment].
    Ehret M; Velter C; Tebacher M; Bruant-Rodier C; Cribier B
    Ann Dermatol Venereol; 2018 Oct; 145(10):607-612. PubMed ID: 29779859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
    Keating GM
    Drugs; 2012 Dec; 72(18):2397-405. PubMed ID: 23231025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results.
    Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Goncalves J; Larsson T; Skov T; Swanson N
    J Drugs Dermatol; 2014 Feb; 13(2):154-60. PubMed ID: 24509965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.